

10-13-2016

The Multi-Morbidity Index: A Tool for Assessing the Prognosis of Patients from History of Illness

Farrokh Alemi

George Mason University, falemi@gmu.edu

Cari R. Levy

Veterans Affairs Medical Center Eastern Colorado Health Care System, Denver, Cari.Levy@va.gov

Raya E. Kheirbek MD, FACP

George Washington University, raya.kheirbek@va.gov

Follow this and additional works at: <http://repository.edm-forum.org/egems>

Recommended Citation

Alemi, Farrokh; Levy, Cari R.; and Kheirbek, Raya E. MD, FACP (2016) "The Multi-Morbidity Index: A Tool for Assessing the Prognosis of Patients from History of Illness," *eGEMs (Generating Evidence & Methods to improve patient outcomes)*: Vol. 4: Iss. 1, Article 19.

DOI: <http://dx.doi.org/10.13063/2327-9214.1235>

Available at: <http://repository.edm-forum.org/egems/vol4/iss1/19>

This Methods Review is brought to you for free and open access by the the Publish at EDM Forum Community. It has been peer-reviewed and accepted for publication in eGEMs (Generating Evidence & Methods to improve patient outcomes).

The Electronic Data Methods (EDM) Forum is supported by the Agency for Healthcare Research and Quality (AHRQ), Grant 1U18HS022789-01. eGEMs publications do not reflect the official views of AHRQ or the United States Department of Health and Human Services.

The Multi-Morbidity Index: A Tool for Assessing the Prognosis of Patients from History of Illness

Abstract

Background: The Multi-Morbidity (MM) Index predicts the prognosis of patients from their diagnostic history. In contrast to existing approaches with broad diagnostic categories, it treats each diagnosis as a separate independent variable using individual ICD-9 codes.

Objective: This paper describes the MM Index, reviews the published data on its accuracy, and provides procedures for implementing the Index within electronic health record (EHR) systems.

Methods: The MM Index was tested on various patient populations by using data from the Veterans Affairs data warehouse and claims data within the Healthcare Cost and Utilization Project of the Agency for Health Care Research and Quality.

Results: In cross-validated studies, the MM Index was more accurate than prognostic indices based on physiological markers; such as CD4 cell counts in HIV/AIDS, HbA1c levels in diabetes, ejection fractions in heart failure, or the 13 physiological markers commonly used for patients in Intensive Care Units. When predicting the prognosis of nursing home patients by using the cross-validated area under a receiver operating characteristic curve (ROC), the MM Index was 15% more accurate than the Quan variant of the Charlson Index, 27% more accurate than the Deyo variant of the Charlson Index, and 22% more accurate than the von Walraven variant of the Elixhauser Index. For patients in Intensive Care Units, the MM Index was 13% more accurate than the cross-validated ROC associated with Elixhauser's categories. The MM Index also demonstrated greater accuracy than a number of commercially available measures of severity of illness; including a five-fold greater accuracy than the All Patient Refined Diagnosis-Related Groups and a three-fold greater accuracy than All Payer Severity-adjusted Diagnosis-Related Groups.

Conclusion: The MM Index is statistically more accurate than many existing measures of prognosis. The magnitude of improvement may lead to a clinically meaningful difference in patient care or policy analysis.

Acknowledgements

This work was supported by appropriation #3620160 from the VA Office of Geriatrics and Extended Care to Dr. Cari Levy at Denver Veterans Affairs, in addition to resources from the District of Columbia Veterans Affairs Medical Center. This article was edited by Peter Gamache, Ph.D.

Keywords

Severity of illness, Prognosis, multiple comorbidities

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License](https://creativecommons.org/licenses/by-nc-nd/3.0/).



The Multimorbidity Index: A Tool for Assessing the Prognosis of Patients from Their History of Illness

Farrokh Alemi, PhD;ⁱ Cari R. Levy, MD, PhD;ⁱⁱ Raya E. Kheirbek, MDⁱⁱⁱ

ABSTRACT

Background: The Multimorbidity (MM) Index predicts the prognosis of patients from their diagnostic history. In contrast to existing approaches with broad diagnostic categories, it treats each diagnosis as a separate independent variable using individual International Classification of Disease, Revision 9 (ICD-9) codes.

Objective: This paper describes the MM Index, reviews the published data on its accuracy, and provides procedures for implementing the Index within electronic health record (EHR) systems. **Methods:** The MM Index was tested on various patient populations by using data from the United States Department of Veterans Affairs data warehouse and claims data within the Healthcare Cost and Utilization Project of the Agency for Health Care Research and Quality.

Results: In cross-validated studies, the MM Index outperformed prognostic indices based on physiological markers, such as CD4 cell counts in HIV/AIDS, HbA1c levels in diabetes, ejection fractions in heart failure, or the 13 physiological markers commonly used for patients in intensive care units. When predicting the prognosis of nursing home patients by using the cross-validated area under a receiver operating characteristic (ROC) curve, the MM Index was 15 percent outperformed the Quan variant of the Charlson Index, 27 percent more accurate than the Deyo variant of the Charlson Index, and 22 percent more accurate than the von Walraven variant of the Elixhauser Index. For patients in intensive care units, the MM Index was 13 percent outperformed the cross-validated area under ROC associated with Elixhauser's categories. The MM Index also demonstrated greater accuracy than a number of commercially available measures of illness severity; including a fivefold greater accuracy than the All Patient Refined Diagnosis-Related Groups and a threefold greater accuracy than All Payer Severity-Adjusted Diagnosis-Related Groups.

ⁱGeorge Mason University, ⁱⁱVeterans Affairs Medical Center Eastern Colorado Health Care System, ⁱⁱⁱGeorge Washington University

CONTINUED

Conclusion: The MM Index is statistically more accurate than many existing measures of prognosis. The magnitude of improvement is large and may lead to a clinically meaningful difference in patient care. Given the large improvements in accuracy, the use of the MM Index for policy and comparative effectiveness analysis is recommended.

Introduction

Prognostic information has many meaningful uses. Patients and clinicians can use it to plan for end of life decisions, such as setting treatment priorities. Policy analysts can use it to evaluate the comparative effectiveness of various treatment options. Administrators can also use it to anticipate patients' acuity and nursing needs. All of these uses presuppose that an accurate measure of prognosis exists. In this paper, we describe and report on the accuracy of the Multimorbidity (MM) Index. Alemi and colleagues¹⁻⁶ developed the MM Index to account for the prognosis of patients with multiple diagnoses.

Several other investigators have also proposed methods for predicting a prognosis from patients' diagnoses. Charlson and colleagues were among the first group of investigators to do so.⁷ These authors developed an index that predicted mortality from 22 broad disease categories, including one category for all heart diseases, another for AIDS, and still another for all cancers. Deyo et al.,⁸ Romano et al.,⁹ Manitoba et al.,¹⁰ and D'Hoores et al.¹¹ attempted to improve on the initial Charlson Index by modifying the broad categories and dropping or adding new categories. Elixhauser and colleagues¹² continued these modifications by creating a list of 30 broad categories of comorbidities, and van Walraven et al. organized these categories into an index.¹³

In contrast to existing approaches, the MM Index does not classify diagnoses into broad disease categories. Instead, it scores the underlying disease. In existing methods, diagnoses with widely varying hazard ratios are scored the same because they fall in the same disease category. For example, consider the variation in mortality among the 28 diagnoses in the "secondary malignancies" category that are used in variants of the Elixhauser Index. In a recent study of the prognosis of heart failure patients,¹⁴ patients who also had a "secondary malignant neoplasm of brain and spinal cord" had an odds ratio of mortality equal to 17.28. In comparison, those who had another variant of a secondary malignancy (i.e., a "secondary neuroendocrine tumor of distant lymph nodes") only had an odds ratio of mortality equal to 2.43. This example illustrates that the same category, secondary malignancies, includes diagnoses that have a nearly ninefold difference in mortality, and that grouping all secondary malignancies into one category overly simplifies the differences within this category. One would anticipate that the accuracy of prognostication could be improved by considering the 28 types of secondary malignancies separately rather than together as one category, which is a feature of the MM Index.

In this paper, we review the design of the MM Index, compare its performance to other prognostic indices, and describe how the index can be used



within an electronic health record (EHR). The paper also includes code for constructing the MM Index in different data sets or for incorporating the method into EHRs.

Derivation of the Multimorbidity Index

The key feature of the MM Index is that it is built from thousands of diagnoses, without classifying these diagnoses into categories. In order to effectively model the relationship between thousands of diagnoses and mortality, the MM Index uses the Naive Bayes data mining model. In this approach, one assumes that the impact of each disease on mortality is independent from other diseases. This assumption is also made in traditional statistical approaches that use linear logistic regression. Even though the assumption is obviously false, numerous studies have shown that the Naive Bayes produces predictions that are as accurate as more complicated models that assume interactions among diseases.¹⁵⁻²⁶ In this approach, the overall probability of mortality is calculated as follows:

$$\text{Patient's MM score} = \prod_{\text{Patient's Diagnoses}} L_{\text{Diagnosis}}$$

where $L_{\text{Diagnosis}}$ indicates the likelihood ratio associated with the diagnostic code in the training data set.

The likelihood associated with each diagnosis is calculated using the following formula from the portion of the data set aside for training of the model:

$$L_{\text{Diagnosis}} = \frac{\text{Prevalence of diagnosis among dead patients}}{\text{Prevalence of diagnosis among alive patients}} = \frac{p(\text{Dx}|\text{Dead})}{p(\text{Dx}|\text{Alive})}$$

The likelihood ratio associated with each diagnosis can be interpreted as the number of times the diagnosis increases the odds of mortality. A likelihood ratio of 2 indicates that the diagnosis

doubles the risk of mortality, while a likelihood ratio of 0.5 indicates that the odds of mortality is reduced by half.

These likelihood ratios were estimated from data within the United States Department of Veterans Affairs (Veterans Affairs) medical records and are publicly available for heart failure¹ and for nursing home patients.² To facilitate the estimation of these ratios for other populations, the Standard Query Language (SQL) code that we had used is provided in the Appendix A.

One problem with the method used to estimate the likelihood ratios is that it is affected by co-occurring diagnoses. Thus, hypertension may receive higher likelihood of mortality if it tends to occur with more serious diseases such as heart failure or shock. Procedures to remove confounding are available in several published papers.²⁷ We recommend the use of Stratified Covariate Balancing (see R Package StratifiedBalancing) in removing confounding as this approach is not parametric and can be done within EHRs using SQL.³¹ Applying methods of removing confounding to the estimation of survival of patients with co-occurring diagnoses remains an active area of research.

Sample Size Needed to Construct the MM Index

To derive the MM Index, it is important to recognize that a large number of parameters are estimated. There are in excess of 14,000 International Classification of Diseases (ICD) codes, and within most populations 3,000–5,000 unique diagnoses occur. This means that approximately 3,000–5,000 parameters must be estimated. There are a number of ways to estimate the sample size that would be needed for such a large number of determinations. Some investigators have suggested that the power of the investigation depends on the ratio of the

number of subjects to the number of variables, using heuristics such as 10 times^{32,33,34} or 20 times³⁵ the number of subjects compared to the number of variables in the model (i.e., in order to estimate 5,000 parameters, 100,000 subjects would be needed). In most of the analyses reported here, the total sample size exceeds 30 times the number of variables, suggesting the estimated model has sufficient power to detect the needed parameters.

Others posit that the most important consideration is the accuracy of local estimates, such as the likelihood ratio associated with each diagnosis.^{36,37} To calculate those likelihood ratios, a sample size formula for a two-sample t-test can be applied to calculate the required sample size for one diagnosis. In multivariate analysis, the impact of a single diagnosis is evaluated within the context of many others. In these situations, a correction factor associated with the percent of variation explained by the covariates is added to inflate the variance and improve the power.^{38,39} In selecting one of these two approaches, one may consider the intended use of the study findings. If an overall index score is of interest, then heuristics that use the ratio of the number of subjects to the number of estimates may be most appropriate. However, if individual likelihood ratios associated with each of the respective diagnoses are of concern, then a more localized estimation of the individual likelihood ratios is needed.

Use of MM Index

Many investigators and clinicians may wish to estimate the probability of mortality at different time intervals (e.g., 6 months, 12 months, or 5 years). By using prior odds of mortality, one can transform the MM Index to estimate the probability of mortality within a specific period. According to the Bayes formula, the posterior odds of mortality are calculated as follows:

$$\text{Posterior odds} = \text{Prior odds} * \text{MM Index}$$

$$\text{Probability of Mortality} = \frac{\text{Posterior Odds}}{1 + \text{Posterior Odds}}$$

Adjustments for Diseases with No Mortality or Mortality in All Cases

Many common diseases are associated with no patient mortality, and there are also rare diseases where every patient dies. In both of these situations, a likelihood ratio cannot be calculated. In these circumstances, Alemi^{40,41} proposed using the following formulas:

$$L_{\text{Diagnosis}} = \begin{cases} \text{if all survive} & 1/(n+1) \\ \text{if none survive} & n+1 \end{cases}$$

where n indicates the number of patients with the diagnosis.

Other adjustments have been reported in the literature, including adding a fraction of a case to either the denominator or the numerator to avoid division by zero. The adjustment used here has the advantage that it is proportional to the number of patients with the diagnosis (i.e., a higher likelihood ratio is assigned when all patients die from diseases that are more frequent). For example, if all 100 patients with a disease died, then the assigned likelihood ratio is 101. This assigned likelihood ratio (i.e., 11) is higher than if all 10 patients with a disease had died.

Adjustment for Rare Diseases

Although the MM Index is derived from a large data repository, there are several diagnoses that are rare and have insufficient observations to estimate a likelihood ratio. In a minority of cases (e.g., when a patient presented with a diagnosis that was not seen in at least 29 cases in the training set), then the likelihood ratio associated with a broader diagnostic category is used to score the patient. A typical International Classification of Disease, Revision 9 (ICD-9) diagnosis is represented as a five-digit



number consisting of three initial digits, a period, and two additional digits. The first three digits represent a disease category. Each additional digit after the period represents further refinements. If the patient's diagnosis is rare, then one could use the likelihood ratio for a broader category of the diagnosis that repeats more often (e.g., by dropping the last digit in the diagnosis code). Appendix A includes the SQL code that can be used to estimate the likelihood ratios associated with three-, four-, and five-digit codes from data in EHRs.

Adjustment for the International Classification of Diseases, Revision 10 (ICD-10)

To date, the MM Index has been evaluated using diagnoses coded with ICD-9. In the International Classification of Diseases, Revision 10 (ICD-10), a sixth digit was added to further clarify the disease categories. The procedures described in this paper and the computer code provided in Appendix A can be used to estimate the prognosis of each code within ICD-10. Because ICD-10 has tenfold more codes than ICD-9, reliable estimates for this version cannot be made until tenfold larger data are available. Even when the data are available, many disease codes in ICD-10 are unlikely to occur with sufficient frequency so that the prognosis for these codes can be estimated reliably. When ICD-10 codes cannot be estimated reliably, investigators should combine data and rely on higher order codes in ICD-9, using the procedures explained earlier for estimating rare diseases. If ICD-10 codes can be estimated reliably, then these codes should be used instead of ICD-9. By using this method, the best description of the patient would be used. When the estimate is not available, a less precise description would be used.

Multidimensional Variant of the MM Index

Because MM Index scores each diagnosis, this leads to a model with thousands of independent variables.

Since clinicians have a difficult time tracking thousands of variables, a solution is needed that would allow the scoring of each diagnosis but would classify the respective diagnoses into a smaller set of dimensions that are easier to manage. Similarly, when evaluating the comparative effectiveness of treatments, there is a need to have sub-indices that indicate the relative severity of different diseases within body systems. The propensity scoring then adjusts for risks introduced by the different body systems and not just the overall mortality risk. The Multidimensional Multiple Morbidity (MMM) Index was created to address this scenario by breaking the overall MM Index into distinct subcategories. A modeling technique used for this purpose is the Multiattribute Utility model. The first application of utility theory to prognosis modeling can be traced to the work of Gustafson and colleagues.⁴² Later applications have included testing of preferential independence assumptions of additive or multiplicative utility models.⁴³ In this approach, each attribute describes a set of comorbidities, typically within the same body system. The overall MMM score is then organized using the following formulas:

$$MMM = 1 - \prod_i (1 - k_i U_i)$$

where:

U_i is the maximum relative severity of disease in the i^{th} category of disease. These scores are scaled to range from 0 to 1, with 1 indicating the score for the worst disease in the category. These scores are made proportional to the hazard rate associated with each disease and are estimated from the data.

k_i is the largest probability of mortality associated with the unconfounded impact of diseases within the i^{th} category.

Table 1 shows examples of how the MMM Index is organized from a progression in three body systems. Three body systems are shown in Table 1, and more are available through the first author.⁴⁴ The columns in the table show the various body systems (e.g., diseases in the circulatory system). Each row in Table 1 corresponds to a particular level of severity. An example for the circulatory system is “1st [hospitalization for] 459.2, Ruptured Abdominal Aortic Aneurysm.” It is assigned a score of 0.4, while “2nd [hospitalization for] 785.51, Cardiogenic Shock” is assigned a score of 1. These scores illustrate the

relative severity within the category of Circulatory System. In essence, the utility scores list the diagnoses within the system (from relatively benign to the most serious) in the order of their hazard rate. This parameter k is the maximum unconfounded probability of mortality within each body system. In this scoring of the body system, each disease is initially rated based on its associated utility score. Then within each body system, the disease with the highest score is selected. Finally, an overall score is calculated by using the MMM formula.

Table 1. Example Body Systems in the Multidimensional Multiple Morbidity Index

UTILITY SCORE	CIRCULATORY SYSTEM	DIGESTIVE SYSTEM	ENDOCRINE, NUTRITION, METABOLIC SYSTEM
0.0	1 st 941.1, Erythema due to 1 st degree Burn Not Otherwise Specified	1 st 997.4 Retained Cholelithiasis Following Cholecystectomy	1 st 244, Benign Neoplasm Pituitary
0.1	2 nd 941 Burn of Face, Head, and Neck	1 st 151.1, Perforation of Intestine	1 st 783.3, Vitamin A Deficiency Not Otherwise Specified
0.2	1 st 996.02, Lower Extremity Embolism	1 st 151.3, Malignant Neoplasm Stomach NOS	
0.3	1 st 428.2, Acute pericarditis in Diseases Classified Elsewhere	1 st 197.4, Malignant Neoplasm Abdomen	1 st 194.9, Malignant Neoplasm Endocrine Not Otherwise Specified
0.4	1 st 459.2, Ruptured Abdominal Aortic Aneurysm	1 st 197.6, Secondary Malignant Neoplasm Peritoneum	4 th 262, Other Severe Malnutrition
0.5	2 nd 425.7, Metabolic Cardiomyopathy	3 rd 197.8, Secondary Malignant Neoplasm Peritoneum	
0.6	1 st 785.5, Shock Not Otherwise Specified		
0.7	3 rd 427.5, Cardiac Arrest	6 th 151.9, Malignant Neoplasm Stomach Not Otherwise Specified	1 st 198.7, Second Malig Neo Adrenal
0.8			
0.9	8 th 428.23, Acute On Chronic Systolic Heart Failure		
1.0	2 nd 785.51, Cardiogenic Shock	1 st 529.8, Epistaxis	2 nd 198.7, Second Malig Neo Adrenal

Note: Repeated hospitalizations for the same diagnosis are scored separately.




Accuracy of the MM Index Compared to Physiological Markers

The health care literature is replete with studies that report the use of physiological markers as prognostic indicators. In this section, the performance of the MM Index is compared to select physiological markers. Aleml and colleagues examined the prognosis of patients with HIV/AIDS by using an MM Index⁴⁵ in 1999 and found that the index was more predictive of patients' survival than an index developed from an average of physiological indicators, such as CD4 T lymphocytes counts. Subsequent analyses by other investigators also demonstrated that the index was accurate in predicting HIV/AIDS prognosis for patients who died in six months and who were eligible for hospice care.⁴⁶ This early attempt at constructing an MM Index did not take into account all diagnoses and was limited to specific diagnoses that followed a diagnosis of HIV/AIDS.

In 2013, a comprehensive MM Index was used to predict 12-month mortality for diabetes patients.⁴⁷ This Index correctly predicted the mortality of 89.9 percent of cases. In as yet unpublished data,⁴⁸ the performance of the diabetes MM Index was compared to the accuracy of Hemoglobin A1c levels for 468,867 diabetic patients. A number of investigators have shown how tight control of, or high levels of, Hemoglobin A1c might affect prognosis.^{49,50,51,52,53} Figure 1 shows that the sensitivity and specificity of the MM Index was superior to prognostic indicators based on HbA1c levels alone. The area under an ROC curve for predicting 6-month mortality for HbA1c levels was 0.652; in contrast the ROC for the MM Index was 0.812. The MM Index was therefore 1.25 times more accurate than the widely used HbA1c levels.

In 2015, the MM Index was used to predict the 6-month mortality of 140,699 nursing home residents.⁵⁴ The cross-validated accuracy of the

Figure 1. Comparison of MM Index and HbA1C in Predicting 12-Month Mortality



MM Index was compared to a common measure of daily functional activity, the Barthel Index.^{55,56} The cross-validated ROC for the MM Index was 0.838. In contrast, the cross-validated ROC for the Barthel Index was 0.692.

Also in 2015, the MM Index was compared to the ejection fraction for 602,050 unique heart failure patients across 130 Veterans Affairs medical centers.⁵⁷ The cross-validated ROC for the MM Index was 0.784. In contrast, the cross-validated ROC for the ejection fraction was only 0.533, which was barely above a random chance event. Ejection fraction was not predictive of long-term mortality rates.

In a study of patients in intensive care, we compared the accuracy of the MM Index to 13 physiological markers.⁵⁸ These markers included the following: (1) sodium, (2) blood urea nitrogen, (3) creatinine, (4) glucose, (5) albumin, (6) bilirubin, (7) white blood cell count, (8) hematocrit, (9) PaO₂, (10) PaCO₂, (11) pH, (12) eGFR, and (13) lactic acid. We examined the 6-month and 12-month mortality of 442,692 unique patients seen in 87 Medical Intensive Care Units of Veterans Affairs Medical Centers between 2003 and 2013. The MM Index, relying solely on diagnostic codes, yielded an ROC of 0.84. In contrast, the logistic regression based on the combined impact of 13 physiological markers yielded a ROC of 0.65. These studies collectively show that the MM Index is more accurate in predicting 6-month or 12-month mortality compared to select physiological makers.

Accuracy of MM Indices Compared to Other Diagnoses-Based Indices


This section compares the MM Index and its variants to the Charlson Index and other diagnoses-based indices. In 2002, the MMM Index was used to predict mortality from childhood diseases.⁵⁹ The source of data was the 2006 Kid's Inpatient Database of the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality. This

database contained data on pediatric (children 20 years of age and younger) discharges from 3,739 community, nonrehabilitation hospitals in 38 states. A total of 3,131,324 unweighted discharges were available. The accuracy of the MMM Index was compared to All Patient Refined Diagnosis-Related Groups,⁶⁰ the All Payer Severity-adjusted Diagnosis-Related Groups,⁶¹ and a simple count of diagnoses.⁶² The MMM Index explained 32 percent of the variation in mortality, as measured by percent of deviance explained in mortality. It was fivefold more accurate than All Patient Refined Diagnosis-Related Groups and threefold more accurate than All Payer Severity-adjusted Diagnosis-Related Groups. This study demonstrated that prognostic information can be significantly improved by scoring each diagnosis separately.

In 2015, the MM Index was directly compared to the Charlson and Elixhauser variants by predicting the 6-month mortality of heart failure patients.⁶³ In this study, the prognosis of 602,050 unique heart failure patients across 130 Veterans Affairs medical centers was studied. The MM Index had a cross-validated ROC of 0.784. The MM Index was more accurate than the Quan variant of the Charlson Index,⁶⁴ with an ROC of 0.656. It was also more accurate than the enhanced⁶⁵ Deyo variant⁶⁶ of the Charlson Index, with an ROC of 0.677. It was more accurate than the von Walraven variant of the Elixhauser Index,⁶⁷ with an ROC of 0.639. It was also more accurate than chronological age with an ROC of 0.649, illustrating the importance of illness over age. Figure 2 compares the performance of these indices against each other. In all of these comparisons, not only was the cross-validated improvement in accuracy achieved by the MM Index statistically significant, but the magnitude of the improvement was large enough to potentially explain away small or medium treatment effects.



Figure 2. MM Index and Variants of the Charlson Index



In the study of intensive care patients (discussed above in the comparison of the MM Index to physiological markers), we also compared the performance of the MM Index to comorbidity categories within the Elixhauser list, immunosuppressant medication use, and age. The study reported the 6-month and 12-month mortality of 442,692 unique intensive care patients. The MM Index relied on 5,695 diagnoses codes. The cross-validated ROC for the MM Index was 0.84. In contrast, the ROC for immunosuppressant medication use was 0.59; for age it was 0.60; for Elixhauser comorbidities it was 0.69; and for all combined variables (including physiological markers) it was 0.80. As in previous studies, these differences were all cross-validated and statistically significant. The fact that the MM Index, which scores each diagnosis, was more accurate than the Elixhauser's categories of comorbidities suggests that grouping diagnoses into broad diagnostic categories reduces the accuracy of predictions.

Methods for Using the MM Index

To illustrate the application of the MM Index to specific cases, we use a case from a recent analysis of the prognosis of nursing home residents. The resident was 81 years old with 10 diagnoses during the last hospital admission (see Table 1). The likelihood ratio of each diagnosis was looked up in the online Table from the George Mason University Dataverse.⁶⁸ For one diagnosis, "chronic airway obstruction, not COPD, and not elsewhere classified," the table does not provide any information and therefore this diagnosis was ignored and scored with a likelihood ratio of 1. The MM score, the product of all likelihood ratios, was calculated as 45.07. In this database, the prior odds of mortality for this population was 0.16. The prior odds was multiplied by the product of the likelihood ratios to obtain the posterior odds. The posterior odds can be expressed as a probability by dividing the posterior odds by one plus the odds. This patient's diagnoses has resulted in a probability of 0.88 for dying in the

next six months. The likelihood ratios in Table 1 can also be used to explain the prediction. Likelihood ratios above 1 indicate diagnoses that increased the odds of mortality. Based on these data, the main reason for the high estimate of mortality pertained to the following: (1) lung cancer, (2) anorexia, and (3) cachexia. Each more than doubled the risk of mortality. Kidney disease also contributed to the high probability of mortality, but to a lesser extent.

The following example can also demonstrate how the MMM variant of the MM Index can be used. A patient presents with the worst disease in the circulatory system (i.e., second hospitalization for cardiogenic shock) and has two diseases within the digestive system (i.e., first hospitalization with

perforation of intestine and first hospitalization for malignant neoplasm of stomach, not otherwise specified). For simplicity, assume that this patient has no other diseases within other body systems. The maximum progression within circulatory disease is 1, and the maximum progression within digestive diseases is 0.2 (the maximum of 0.1 and 0.2). For all other categories, there is no progression and they are scored 0. The overall probability of death for the patient is then calculated as follows:

$$MMM = 1 - (1 - 1.0 \times 0.74)(1 - 0.20 \times 0.81) = 0.78$$

Note that in this method of scoring, any diagnosis with elevated risk, no matter how benign, always increases the probability of mortality.

Table 2. Calculation of the MM Index from Diagnoses of an 81-Year-Old Resident

DESCRIPTION OF DIAGNOSIS		LIKELIHOOD RATIO
(1)	Malignant neoplasm of upper lobe, bronchus, or lobe	3.18
(2)	Other specified chronic ischemic heart disease	1.41
(3)	Abdominal aneurysm without mention of rupture	1.04
(4)	Peripheral vascular disease, unspecified	0.96
(5)	Chronic airway obstruction, not COPD, and not elsewhere classified	Not Found
(6)	Chronic kidney disease, stage IV (severe)	1.45
(7)	Secondary hyperparathyroidism of renal origin	1.03
(8)	Anorexia	2.16
(9)	Nausea and vomiting	1.02
(10)	Cachexia	3.06
STEPS IN CALCULATION		RESULTS
MM Index (product of all likelihood ratios)		45.07
Prior odds for all residents		0.16
Posterior odds for this case (prior odds times MM Index)		7.21
Probability of Mortality (posterior odds divided by 1 plus posterior odds)		0.88



Derivation of the MM Index from Data in an Electronic Health Record (EHR)

To facilitate the use of the MM Index in different EHR systems, Appendix A contains an SQL code that will facilitate the estimation of the parameters of the Index for a specific cohort of patients within a data warehouse. While we have experience with ICD-9 codes, a similar SQL can be run for ICD-10, thereby allowing the EHR to adjust for changes in the coding procedures. In addition, a similar SQL code can be run for procedures, exposure to medications, and categorized physiological measures, as well as decades of age, thereby allowing the prognostic index to reflect more than diagnoses.

Conclusion

This paper reviews the recent methodological research on the performance and application of the MM Index. One finding of this review was that MM Index had higher ROC than various physiological measures of prognosis, including ejection fraction for heart failure, HbA1c levels for diabetic patients, and 13 physiological measures for patients in intensive care units. Clinicians may prefer relying on physiological measures for any of the following reasons:

1. Many are concerned with coding errors in reporting patient diagnoses.⁶⁹ However, given the accuracy of the results reported in this paper, coding errors are not extensive enough to significantly reduce the accuracy of diagnosis-based indices.
2. Some clinicians are concerned with reports that diagnoses in administrative data are less accurate than physiological markers when predicting prognosis, e.g., Brinkman et al.⁷⁰ These studies do not contradict the data presented in this paper. These studies compare the accuracy of broad categories of diagnoses and not individual

diagnoses. As reviewed, when diagnoses are not grouped into broad categories, the results are radically different and worse than when each diagnosis is scored.

3. Some clinicians prefer to use physiological markers because they often use these markers in patient management. Clearly, abnormal physiological markers raise the chances of mortality, but physiological markers are often transient and return to normal with good care. There is no reason to believe that these variations affect long-term mortality six months later.

A major conclusion of this paper was that MM Index is more accurate than existing diagnosis-based indices, such as variants of Charlson and Elixhauser indices. To the best of our knowledge, the MM Index is the first index that scores each disease separately rather than grouping similar diagnostic codes into broad categories. The observed improved accuracy of the MM Index may be due to this feature of its scoring.

The comprehensive inclusion of thousands of comorbidities in the MM Index makes its use within clinical settings more difficult. To address use in clinical settings, the paper also described the MMM variant of the MM Index. The MMM variant still scores each disease but classifies these diseases by body system after scoring and selects the maximum (worst) score within each body system. This organization of diagnoses in various body systems allows clinicians to think through the prognosis of their patients more intuitively and without access to a computer. The MMM Index is also helpful for conducting a propensity-matched comparative effectiveness study, where cases and controls must have similar scores across different body systems. Matching on scores ranges in the body systems may be more practical than matching on separate diagnoses within the body system.

Use of the MM Index is more practical now that many clinics have access to EHRs. These computers have access to the patients' diagnostic history, can score patient's prognosis, and can explain the top two or three reasons for the predicted prognosis. Then, the use of MM Index in a clinical setting will be akin to use of any laboratory test, where the results are available but details of how the results were obtained are masked.

The Appendix to this paper (as well as CIELO repository) provides an SQL code that can be used to estimate the parameters of the MM Index from data within warehouses or EHR systems. This code allows investigators to estimate the parameters of the MM Index for the population that they are working with. It can also be easily incorporated into the design and operations of an EHR.

There are a number of ways that the MM Index can be further improved, including the examination of interaction among diseases and removal of confounding in estimates of likelihood ratios. In addition, the MM Index may be improved if medications, physiological markers, or procedures were used to predict prognosis.

The use of the MM Index, as well as other prognostic indices, is fraught with difficulties when personalizing data for one patient. The MM Index reflects average probabilities associated with a disease. No patient is the average patient, since patients are likely to experience a combination of comorbidities that may radically differ from the average patient.

Furthermore, a discussion of mortality with patients may be understood differently if it is framed in terms of survival as opposed to mortality. Probabilities may be misunderstood, and patients may prefer to know expected survival days as opposed to the probability of mortality in six months. Obviously, any discussion of prognosis with patients requires empathetic communication on the part of clinicians. These and other limitations continue to frustrate efforts to make data on prognostic information available to patients and their families. Additional research is needed to clarify how to best communicate prognostic information to individual patients.

The MM and MMM Indices can be used easily in policy analysis, decision support, and program evaluation. In these uses, the index enables assessment of comparative effectiveness of treatment. Because these indices are more accurate than existing comprehensive diagnosis-based indices, we recommend their use despite the complexity of the underlying scoring procedures.

Acknowledgments

This work was supported by appropriation #3620160 from the VA Office of Geriatrics and Extended Care to Dr. Cari Levy at Denver Veterans Affairs, in addition to resources from the District of Columbia Veterans Affairs Medical Center. This article was edited by Peter Gamache, Ph.D. The views expressed in this paper do not represent the views of the Veterans Administration or the United States Government.



Appendix A

The SQL code for the derivation of parameters of the Multimorbidity (MM) Index is provided below. Similar SQL code is also available for measurement of episodes of illness.⁷¹ Because the source of data may include millions of records, the code is written in steps, with each step generating a temporary or a permanent file that is used in subsequent steps. In this fashion, if for some reason the server operations are interrupted, intermediary results are still available and one can start the analysis from the point of the interruption and not from the beginning.

In the first step, we select 80 percent of the cases for calculations of the likelihood ratios and set aside the remaining cases for validation purposes:

```

*****
--> 1. Make data for training cases From 602,050 patients
*****
/* The data for these tables come from VA Informatics and Computing Infrastructure. These tables include the study cohort, patient
information, outpatient encounters, inpatient encounters as well as other information. All patient identifiers are removed from the data.
Across different stations, patients have the same scrambled social security number and International Classification of Disease codes */

/* Split data into training and validation sets. Randomly select 80% of cases for training. This is needed for cross-validating study findings. */

Print 'Generate a random number'
Drop table #tmp1
SELECT DISTINCT [ScrSSN], Rand(cast(newid() as varbinary)) AS RR
INTO #tmp1
FROM [Src[CohortScrSSN]]
Go -- (948,236 row(s) affected)

Print 'Select 80% of cases'
DROP TABLE #tmp2
SELECT ScrSSN
INTO #tmp2
FROM #tmp1
WHERE RR<.8
Go -- (759107 row(s) affected)

Print 'Get date of birth and death'
DROP TABLE #tmp3
SELECT b.[ScrSSN] as ssnID
, Max(DateOfDeath) AS DeathDate
, Max(DateOfBirth) AS BirthDate
INTO #tmp3
FROM #tmp2 a inner join [Src[CohortCrosswalk]] b on a.scrssn=b.scrSSN
inner join [Src[SPatient_SPatient]] c on b.patientsid =
c.patientsid and b.sta3n=c.sta3n
WHERE DateOfBirth is not null
GROUP BY b.scrSSN
Go -- (716272 row(s) affected)

Print 'Store as training cases'
DROP TABLE dflt.tcases
SELECT *
INTO dflt.tCases
FROM #tmp3
Go -- (716272 row(s) affected)

```

In the second set of steps, we calculate the length of service to a patient. This information is used to exclude patients who are not deceased but have no visit after a certain date for at least one year. These patients are likely to have changed providers and may be receiving care outside of Veterans Administration.

Use [Database]

```
>*****
-->          Calculate last encounter.
--> ***** 1 hour 42 min *****
```

```
USE          [Database]
```

Print 'Get last outpatient visit dates for training cases'

```
DROP TABLE #LastVisit
SELECT      t.ssnID, Max(VisitDateTime) as LastVisit, Min(visitdatetime) as
            FirstVisit
INTO        #LastVisit
FROM        [dflt[tcases] t left join [Src[CohortCrosswalk] c on t.ssnID           = c.scrssn
            left join [Src[Output_Visit] o on c.PatientSID=o.Patientsid         And
            c.Sta3n=o.sta3n
WHERE       VisitDateTime is not null
GROUP BY   t.ssnID
Go -- (714820 row(s) affected) 39 minutes
```

Print 'Get last hospital admission date for training cases'

```
DROP TABLE #LastAdm
SELECT      t.ssnID
            , max([AdmitDateTime]) as LastAdmit
            , min(admitdatetime) as FirstAdmit
INTO        #LastAdm
FROM        [dflt[tcases] t left join [Src[CohortCrosswalk] c on t.ssnID           = c.scrssn
            left join [Src[Inpat_InpatientDiagnosis] i on c.PatientSID =
            i.Patientsid And
            c.Sta3n=i.sta3n
WHERE       admitdatetime is not null
GROUP BY   t.ssnID
Go -- (661407 row(s) affected)
```

Print 'Combine last visit and last admit'

```
DROP TABLE #t1
SELECT      ssnID, lastadmit, Firstadmit into #t1 from #lastAdm
UNION all
SELECT      ssnID, LastVisit, FirstVisit from #lastvisit
Go -- 1376227 row(s) affected)
```

Print 'Select last encounter'

```
DROP TABLE dflt.LastEnc
SELECT      ssnid, max(lastadmit) as lastEnc, min(firstadmit) as FirstEnc
INTO        dflt.lastEnc
FROM        #t1
GROUP BY   ssnid
Go -- (714854 row(s) affected)
```

Print 'Remove cases with less than 1 year of follow up'

```
DELETE FROM Dflt.LastEnc WHERE datediff(dd,firstEnc,LastEnc)<365
Go -- (19928 row(s) affected) Deleted
```




In the third step, the likelihood ratios are estimated from the data within the database.

```
*****
--> ***** Calculate Likelihood Ratios from training cases
*****
```

```
USE [Database]

Print 'Delete cases with less than 1 year follow up'
DROP TABLE #tcases
SELECT t.*, lastEnc
INTO #tcases
FROM dflt.tcases t inner join dflt.LastEnc l on t.ssnID=l.ssnID
Go
--(694926 row(s) affected)

Print 'Get inpatient diagnoses for training cases'
DROP TABLE #Dx0
SELECT ssnID, i.patientsid, i.sta3n
, admitdatetime, lastEnc, deathdate
, icd9sid
, iif(deathdate is null
, iif(datediff("dd", admitdatetime, LastEnc)<182, 1.0)
, iif(datediff("dd", admitdatetime, deathdate)<182, 1.0)) As
Dead182
, datediff("dd", birthdate, [AdmitDateTime]) As AdmAgeInDays
, datediff("yy", birthdate, [AdmitDateTime]) As AdmAgeInYears
INTO #Dx0
FROM #tcases t left join [Src[CohortCrosswalk] c on t.ssnID =
left join [Src[Inpat_InpatientDiagnosis] i on
c.PatientSID=i.Patientsid And c.Sta3n=i.sta3n
WHERE [AdmitDateTime] is not null
-- (35889752 row(s) affected) Diagnoses
Go

Print 'Identify patients with encounters after death'
DROP TABLE #BadDate
SELECT ssnID, admitdatetime, lastenc
INTO #BadDate
FROM #Dx0
WHERE datediff(dd, admitdatetime, lastenc)<-1
Go
-- 0 (0 row(s) affected)

Print 'Get ICD9 codes and descriptions, different stations have same codes'
DROP TABLE #ICDCode
SELECT icd9sid, max(icd9code) as ICD9Code, Max([ICD9Description]) as
Max([DiagnosisText]) as Short
INTO #ICDCode
FROM [CDWork[Dim[ICD9]
GROUP BY ICD9SID
Go
-- (2,025,871 row(s) affected)

Print 'Rank order repeated diagnosis, select good date of admissions'
DROP TABLE dflt.tDx
SELECT DISTINCT
```

```

        d.ssnID as id1, d.admitdatetime
        , icd9code, left(icd9code, 6) as ICD6, left(icd9code, 5) as icd5, left(icd9code,4)
as icd4, left(icd9code,3) as icd3
        , Dead182, Long, Short
        , rank() Over (Partition by d.ssnid, icd9code Order by
d.admitdatetime) as Repeated
INTO      dflt.tDx
FROM      #dx0 d left join #Baddate b on d.ssnID=b.ssnID
        left join #icdcode i on d.icd9sid=i.ICD9SID
WHERE     b.ssnID is null and icd9code not like '%unkn%'
Go        -- (30800108 row(s) affected)

```

```

>*****
-->          3. Caclualte Likelihood Ratios for ICD9 codes
>*****

```

Print 'Calculate number of occurences for diagnoses with 6 digits'

```

DROP TABLE #dx1
SELECT      icd6
        , Repeated
        , count(distinct id1) as n6Dx
        , sum(dead182) as n6DeadAndDx
        , sum(1-dead182) as n6AliveAndDx
        , 'HospDx6' as IndType
        , Min(Long) as Long
        , Min(Short) as Short
INTO      #dx1
FROM      dflt.tdx
WHERE     len(icd6)=6
GROUP BY  icd6, Repeated
HAVING    count(distinct id1)>29
Go        -- (10928 row(s) affected)

```

Print 'Calculate number of occurences for diagnoses with 5 digits'

```

DROP TABLE #dx2
SELECT      icd5
        , Repeated
        , count(distinct id1) as n5Dx
        , sum(dead182) as n5DeadAndDx
        , sum(1-dead182) as n5AliveAndDx
        , 'HospDx5' as IndType
        , iif(Min(Long)=max(Long),Min(Long),") as Long
        , iif(Min(Short)=max(short),Min(Short),") as Short
INTO      #dx2
FROM      dflt.tdx
WHERE     len(icd5)=5
GROUP BY  icd5, Repeated
HAVING    count(distinct id1)>29
Go        --

```

Print 'Calculate number of occurences for diagnoses using 4 digits'

```

DROP TABLE #dx3
SELECT      icd4
        , Repeated

```



```

, count(distinct id1) as n4Dx
, sum(dead182) as n4DeadAndDx
, sum(1-dead182) as n4AliveAndDx
, 'HospDx4' as IndType
, iif(Min(Long)=max(Long),Min(Long),'') as Long
, iif(Min(Short)=max(short),Min(Short),'') as Short
#dx3
dflt.tdx
WHERE len(icd4)=4
GROUP BY icd4, Repeated
HAVING count(distinct id1)>29
Go
-- (7211 row(s) affected)

Print 'Add 6, 5 and 4 digit diagnoses'
DROP TABLE #dx4
SELECT
    icd6 as Indicator, n6Dx as nDx, Repeated
    , n6DeadAndDx as nDeadAndDx, n6AliveAndDx as nAliveAndDx
    , IndType as [Type], Long, Short into #dx4 from #dx1

UNION all
SELECT
    icd5, n5Dx, Repeated
    , n5DeadAndDx, n5AliveAndDx, IndType, Long, Short from #dx2

UNION all
SELECT
    icd4, n4Dx, Repeated, n4DeadAndDx, n4AliveAndDx
    , IndType, Long, Short
FROM #dx3
Go
-- (32118 row(s) affected)

Print 'Calculate Likelihood Ratio for ICD Code'
DECLARE @nDead int, @nAlive int
SELECT @nDead=sum(nDeadAndDx), @nAlive=sum(nAliveAndDx) from #dx4
DROP TABLE Dflt.LR
SELECT
    [Type], Indicator, Repeated, concat([type]
    ,',', Indicator, ',', Repeated) as Code
    , @nDead as 'Admissions Dead'
    , @nAlive as 'Admissions Alive'
    , nDeadAndDx '# Dead w', nAliveAndDx '# Alive w'
    , nDx as 'Cases w'
    , iif(nDeadAndDx=0, 1.0/cast((nDx+1) as float)
    , iif(nAliveAndDx=0, nDx+1, (cast(nDeadandDx as
float)/cast(@nDead as float))/(cast(nAliveandDx as
float)/cast(@nAlive as float)))) as LR
    , Long, Short
Dflt.LR
#dx4
Go
-- (32118 row(s) affected)

```

References

1. Kheirbek RE, Alemi F, Fletcher R. Heart failure prognosis: comorbidities matter. *J Palliat Med.* 2015 May;18(5):447-52
2. Levy C, Kheirbek R, Alemi F, Wojtusiak J, Sutton B, Williams AR, Williams A. Predictors of six-month mortality among nursing home residents: diagnoses may be more predictive than functional disability. *J Palliat Med.* 2015 Feb;18(2):100-6.
3. Alemi F, Prudius V. A Mathematical Theory for Identifying and Measuring Severity of Episodes of Care. Patent application 10,054,706 filed on 1/24/2002 by George Mason University.
4. Alemi F, Walker L, Carey J, Leggett J. Validity of three measures of severity of AIDS for use in health services research studies. *Health Serv Manage Res.* 1999 Feb;12(1):45-50.
5. Kheirbek RE, Alemi F, Zargoush M. Comparative effectiveness of hypoglycemic medications among veterans. *J Manag Care Pharm.* 2013 Nov-Dec;19(9):740-4.
6. Alemi F, Uriyo M. Accuracy of Claims-Based Measures of Severity of Childhood Illnesses. *Health Outcomes Research in Medicine* (2011) 2, e71-e78.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. "A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation". *Journal of Chronic Diseases* 1987, 40 (5): 373-83.
8. Deyo, R; Cherkin, DC; Ciol, MA (1992). "Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases". *Journal of Clinical Epidemiology* 45 (6): 613-9.
9. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. *J Clin Epidemiol* 1993; 46(10):1075-1079.
10. Roos LL, Walld RK, Romano PS, Roberecki S. Short-term mortality after repair of hip fracture. Do Manitoba elderly do worse? *Med Care* 1996; 34(4): 310-326.
11. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. *Methods Inf Med.* 1993 Nov; 32(5): 382-7.
12. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care.* 1998 Jan; 36(1): 8-27.
13. Van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. *Medical Care* 2009, 47 (6): 626-33.
14. Kheirbek RE, Alemi F, Fletcher R. Heart failure prognosis: comorbidities matter. *J Palliat Med.* 2015 May;18(5):447-52
15. Hand DJ, Yu K. Idiot's Bayes-Not So Stupid After All? *International Statistical Review* Vol. 69, No. 3 (Dec., 2001), pp. 385-398
16. Titterton DM, Murray GD, Murray LS, Spiegelhalter DJ, Skene AM, Habbema JDF, Gelpke GJ. Comparison of discrimination techniques applied to a complex data set of head injured patients. *Journal of Royal Statistical Society* 1981, Series A, 144. 145-175.
17. Monti S, Cooper GF. A Bayesian network classifier that combines a finite mixture model and a naive Bayes model. In *Proceedings of the 15th Conference on Uncertainty in AI*, Stockholm, Sweden, 1999.
18. Nordyke R, Kulikowski CA, Kulikowski CW. A comparison of methods for the automated diagnosis of thyroid dysfunction. *Computers and Biomedical Research*, 4, 374-389, 1971.
19. Todd BS, Stamper R. The relative accuracy of a variety of medical diagnostic programmes. *Methods of Information in Medicine* 1994, 33, 402-416.
20. Gammerman A, Thatcher AR. Bayesian diagnostic probabilities without assuming independence of symptoms. *Methods of Information in Medicine* 1991, 30, 15-22.
21. Croft DJ, Mitchol RE. Mathematical models in medical diagnosis. *Ann Biomed. Engng* 1987. 2: 69-89.
22. Ohmann C, Yang Q, Kiinneke M, Stoltzing H, Thon K, Lorenz W. Bayes theorem and conditional dependence of symptoms: different models applied to data of upper gastrointestinal bleeding. *Methods of information in Medicine* 1988, 27: 73-83
23. de Dombal FT, Leaper DJ, Staniland JR, McCann A, Horrock J. Computer aided diagnosis of acute abdominal pain. *British Medical Journal* 1972, 2:9-13.
24. Bailey NTJ. Probability methods of diagnosis based on small samples. In *Mathematics and Computer Science in Biology and Medicine* 1964. 103-107.
25. Boyle JA, Greig WR, Franklin DA, Harden RM, Buchanan WW, McGirr, E. (1966). Construction of a model for computer-assisted diagnosis: application to the problem of non-toxic goitre. *Quarterly Journal of Medicine* 1966. 35, 565-588.
26. Fryback DG. Bayes' theorem and conditional non-independence of data in medical diagnosis. *Computers and Biomedical Research* 1978. 11: 423-434.
27. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983, 70, 41-55.
28. Imbens GW. The role of the propensity score in estimating dose-response functions. *Biometrika* 2000, 87, 706-710.
29. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. *Statist. Med.* 2004, 23, 2937-2960.
30. Stuart EA. Matching methods for causal inference: a review and a look forward. *Statist. Sci.* 2010, 25, 1-21.
31. Alemi F, ElFardey A, Avramovic I, Stratified Covariate Balancing. *Health Services Research* (in second review 2016) and available through Alemi at falemi@gmu.edu
32. MacCallum, R. C., Widaman, K. F., Zhang, S., & Hong S. (1999). Sample size in factor analysis. *Psychological Methods*, 4, 84-99.
33. Hutcheson G, Sofroniou N. *The multivariate social scientist: Introductory statistics using generalized linear models.* 1999 Thousand Oaks, CA: Sage Publications.
34. Garson DG. *Factor Analysis: Statnotes.* Retrieved March 22, 2008, from North Carolina State University Public Administration Program, <http://www2.chass.ncsu.edu/garson/pa765/factor.htm>.
35. Hogarty KY, Hines CV, Kromrey JD, Ferron JM, Mumford KR. The quality of factor solutions in exploratory factor analysis: The influence of sample size, communality, and over-determination. *Educational and Psychological Measurement*, 65, 202-226.



36. McDonald RP, Krane WR. A note on local identifiability and degrees of freedom in the asymptotic likelihood ratio test. *British Journal of Mathematical and Statistical Psychology* 1977, 30, 198-203.
37. McDonald RP, Krane WR. A Monte Carlo study of local identifiability and degrees of freedom in the asymptotic likelihood ratio test. *British Journal of Mathematical and Statistical Psychology*, 1979, 32, 121-132.
38. Hsieh FY, Lavori PW, Cohen HJ, Feussner JR. An overview of variance inflation factors for sample-size calculation. *Eval Health Prof.* 2003 Sep;26(3):239-57
39. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. *Stat Med.* 1998 Jul 30;17(14):1623-34.
40. Alemi F, Prudius V. A Mathematical Theory for Identifying and Measuring Severity of Episodes of Care. Patent application 10,054,706 filed on 1/24/2002 by George Mason University.
41. Alemi F. Sentiment Analyzer. Patent Application 20130173254, Filed: December 22, 2012, Issued: July 4, 2013.
42. Gustafson DH, Fryback DG, Rose JH, Yick V, Prokop CT, Detmer DE, Moore J. A decision theoretic methodology for severity index development. *Med Decis Making.* 1986 Jan-Mar; 6(1):27-35.
43. Fryback DG, Keeney RL. Constructing a Complex Judgmental Model: An Index of Trauma Severity. *Management Science* 1983, 29(8), 869-883.
44. Tuck MG, Alemi F, Shortle JF, Hesdorffer C. A Comprehensive Index for Predicting Risk of Anemia from Patients' Diagnoses. Available through Alemi at falemi@gmu.edu
45. Alemi F, Walker L, Carey J, Leggett J. Validity of three measures of severity of AIDS for use in health services research studies. *Health Serv Manage Res.* 1999 Feb;12(1):45-50.
46. Kinzbrunner B, Pratt MM. Severity index scores correlate with survival of AIDS patients. *Am J Hosp Palliat Care.* 1994 May-Jun; 11(3):4-9.
47. Kheirbek RE, Alemi F, Zargoush M. Comparative effectiveness of hypoglycemic medications among veterans. *J Manag Care Pharm.* 2013 Nov-Dec;19(9):740-4.
48. Alemi F, Avramovic S, Aron D, Hua M. Prognosis of diabetic patients, 2015 Available through Alemi at falemi@gmu.edu
49. Port SC, Goodarzi MO, Boyle NG, Jennrich RI. Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease. *Am Heart J.* 2005;150:209-214
50. Lenters-Westra E, Slingerland RJ. Hemoglobin A1C determination in the A1C-Derived Average Glucose (ADAG) study. *Clin Chem Lab Med.* 2008;46:1617-1623.
51. Van Leiden HA, Moll AC, Dekker JM, Abramoff MD, Polak BC. Photography or ophthalmoscopy for detection of diabetic retinopathy? *Diab Care.* 2003;26:1318-1319.
52. DCCT Research Group. The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the diabetes control and complications trial. *Diabetes.* 1995; 44:968-983.
53. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ.* 2000; 321:405-412.
54. Levy C, Kheirbek R, Alemi F, Wojtusiak J, Sutton B, Williams AR, Williams A. Predictors of six-month mortality among nursing home residents: diagnoses may be more predictive than functional disability. *J Palliat Med.* 2015 Feb;18(2):100-6.
55. Godfrey J, Poole L. An audit of the use of the Barthel Index in palliative care. *Int J Palliat Nurs.* 2007 Nov;13(11):543-8.
56. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. *Md State Med J.* 1965 Feb; 14:61-5.
57. Kheirbek RE, Alemi F, Fletcher R. Heart failure prognosis: comorbidities matter. *J Palliat Med.* 2015 May;18(5):447-52.
58. Min H, Alemi F, Avramovic S, Wojtusiak J, Khosla R, Fletcher RD, Kheirbek RE. Comprehensive Multi-Morbidity Index for predicting mortality after intensive care. *Journal of Palliative Care* (in 2nd review, 2016).
59. Alemi F, Uriyo M. Accuracy of Claims-Based Measures of Severity of Childhood Illnesses. *Health Outcomes Research in Medicine* (2011) 2, e71-e78. Available at <http://openonlinecourses.com/ehr/Accuracy%20of%20claims%20based%20measures%20of%20childhood%20severity%20of%20illness.pdf>
60. Goldfield N, Averill R On "risk-adjusting acute myocardial infarction mortality: are APR-DRGs the right tool"? *Health Serv Res.* 2000;34(7): 1491-1495. discussion 1495-1498.
61. Averill RF, Goldfield NI, Muldoon J, Steinbeck BA, Grant TM. A closer look at all patient refined DRGs. *J AHIMA.* 2002;73(1):46-50.
62. Wang PS, Walker A, Tsuang M, Orav EJ, Levin R, Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. *J Clin Epidemiol.* 2000; 53(6): 571-578.
63. Kheirbek RE, Alemi F, Fletcher R. Heart failure prognosis: comorbidities matter. *J Palliat Med.* 2015 May;18(5):447-52.
64. Quan H, Sundararajan V, Halfon P, et al.: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005; 43:1130-1139.
65. Wang L, Porter B, Maynard C, Bryson C, Sun H, Lowy E, McDonnell M, Frisbee K, Nielson C, Fihn SD. Predicting risk of hospitalization or death among patients with heart failure in the veterans health administration. *Am J Cardiol.* 2012 Nov 1;110(9):1342-9.
66. Deyo R, Cherkin DC, Ciol MA (1992). "Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases". *Journal of Clinical Epidemiology* 45:613-619.
67. von Walraven C, Austin PC, Jennings A, et al.: A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. *Medical Care* 2009; 47:626.
68. Levy C, Kheirbek R, Alemi F, Wojtusiak J, Sutton B, Williams AR, Williams A. Predictors of 6-Month Mortality among Nursing Home Residents: Diagnoses May be More Predictive than Functional Disability. *George Mason University Data* 2014 http://hdl.handle.net/1902.29/11763_V3 [Version]
69. Campbell SE, Campbell MK, Grimshaw JM, Walker AE. A systematic review of discharge coding accuracy. *J Public Health Med.* 2001 Sep; 23(3): 205-11.

70. Brinkman S, Abu-Hanna A, van der Veen A, de Jonge E, de Keizer NF. A comparison of the performance of a model based on administrative data and a model based on clinical data: effect of severity of illness on standardized mortality ratios of intensive care units. *Crit Care Med*. 2012 Feb;40(2):373-8
71. Alemi F, Walters SR. A mathematical theory for identifying and measuring severity of episodes of care. *Qual Manag Health Care*. 2006 Apr-Jun;15(2):72-82.